Pfizer Translational Oncology Lead in La Jolla, California
As a core member of clinical project teams, this individual is responsible for developing and implementing a robust clinical biomarker plan that translates our preclinical knowledge into competitive strategies for programs moving into early clinical development, and driving bench to bedside and bedside to bench learning.
Develop scientifically rigorous clinical translational research strategies that identify the most attractive patient population and/or select patients for enrollment, determine Proof of Mechanism, establish early Signs of Efficacy, illuminate mechanisms of resistance, and drive combinations.
Analyze, interpret and report results of clinical biomarker analyses, including support of regulatory filings.
Partner collaboratively across integrated, multi-functional clinical teams encompassing development (e.g. clinical, clinical pharmacology, statistics, development operations) and research (e.g. close interactions with biologists and computational scientists), clinical biomarker assay specialists, diagnostics and asset leaders while fostering a culture of scientific excellence and innovation.
Be a nexus for bedside to bench and bench to bedside learnings by communicating and leveraging findings broadly across the organization.
Assess state of the art technologies, collaborate closely with computational and systems biologists, and innovate with academic collaborators to expand clinical translational research.
"Candidate demonstrates a breadth of diverse leadership experiences and capabilities including: the ability to influence and collaborate with peers, develop and coach others, oversee and guide the work of other colleagues to achieve meaningful outcomes and create business impact."
Advanced degree (PhD, MD, MD/PhD, Pharm. D.) or equivalent experience, with focus on cancer biology and a minimum of 5 years of experience in Oncology drug discovery and development. Candidates should possess a sophisticated understanding of modern cancer biology, cancer genetics and immuno-oncology, with a documented focus on translational research and clinical biospecimen analysis in phase 1 clinical trials.
Demonstrated excellence designing, executing and interpreting studies of cancer biomarkers in clinical trials, including biomarker development, validation and clinical application.
Experience with computational, systems and statistical analysis such as scripting, Spotfire, JMP or R programming.
Ability to drive interactions at the interface between lab bench-based research and early clinical development up to proof of concept studies.
Significant external scientific influence within the academic community, publication of primary research results in high-quality, peer-reviewed journals and national/international scientific reputation.
Direct experience or familiarity with state-of-the-art technologies applicable to cancer biomarker or immune response analysis such as next-generation sequencing, immunohistochemistry, immunofluorescence, flow cytometry, in situ hybridization, gene expression profiling, and digital image analysis.
Demonstrated ability to think strategically and creatively while contributing to multiple projects, thrive in a highly collaborative, multi-disciplinary team setting; highly effective verbal and written communication skills.
Experience with multiple modalities (e.g. small molecules, nanoparticles, antibodies, antibody-drug conjugates, bispecifics).
Experience with both cell-autonomous and tumor microenvironment mechanisms.
Demonstrated ability to thrive in matrix organizations.
Experience leveraging genomic and molecular information from patients with extraordinary responses in early stage clinical trials to guide clinical development.
• Relocation eligible
• Eligible for employee referral bonus
Pfizer reports payments and other transfers of value to health care providers as required by federal and state transparency laws and implementing regulations. These laws and regulations require Pfizer to provide government agencies with information such as a health care provider's name, address and the type of payments or other value received, generally for public disclosure. Subject to further legal review and statutory or regulatory clarification, which Pfizer intends to pursue, reimbursement of recruiting expenses for licensed physicians may constitute a reportable transfer of value under the federal transparency law commonly known as the Sunshine Act. Therefore, if you are a licensed physician who incurs recruiting expenses as a result of interviewing with Pfizer that we pay or reimburse, your name, address and the amount of payments made currently will be reported to the government. If you have questions regarding this matter, please do not hesitate to contact your Talent Acquisition representative.
EEO & Employment Eligibility
Pfizer is committed to equal opportunity in the terms and conditions of employment for all employees and job applicants without regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, disability or veteran status. Pfizer also complies with all applicable national, state and local laws governing nondiscrimination in employment as well as work authorization and employment eligibility verification requirements of the Immigration and Nationality Act and IRCA. Pfizer is an E-Verify employer.